NYSE · ENOV

Enovis Corporation

$28.25 +$1.22 (+4.51%) 1D After hours

Key Metrics

$1.56B
Market cap
P/E · TTM
$2.28B
Revenue · TTM
−$1.14B
Net income
EPS · TTM $-20.02
Dividend yield
Free cash flow $35.92M
Beta · 1Y 1.53
EBITDA · TTM $244.61M
Gross margin 60.5%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 6
    The stock moved +15.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 6
  • Jul 1
    From its May 7 high, the share price fell 26%.

    Peak close $27.25 on May 7; trough close $20.04 on Jul 1. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -26%
  • Feb 26
    The stock moved +13.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.56B
Enterprise value$2.85B
Shares outstanding57.6M
52-wk range$19.14 – $34.28
Avg volume · 20D711.5K
Net cash −$1.29B
Book value / share$26.01
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNYSE
About Enovis Corporation
IPO dateMay 8, 2008
Employees7802

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.68
P/FCF43.31
EV/EBITDA11.65
EV/Sales1.25
Graham №

Profitability

Gross 60.5%
Operating -48.3%
Net -49.9%
FCF 1.6%
ROE / ROIC -56.3% · -41.0%

Financial Health

Current ratio2.04
Quick ratio1.05
Debt / equity0.90
Debt / EBITDA 5.42
Net cash −$1.29B
Working capital$631.02M

Cash Flow · TTM

Operating CF $242.84M
Capex −$206.92M
Free cash flow $35.92M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-0.3
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-04-03 · computed by TickerWolf from SEC filings